help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by ORSIDA, B. E.
Right arrow Articles by WALTERS, E. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by ORSIDA, B. E.
Right arrow Articles by WALTERS, E. H.

Am. J. Respir. Crit. Care Med., Volume 165, Number 7, April 2002, 1010-1014

Clinical Relevance of Airway 11beta -Hydroxysteroid Dehydrogenase Type II Enzyme in Asthma

BERNADETTE E. ORSIDA, ZYGMUNT S. KROZOWSKI, and E. HAYDN WALTERS

Department of Respiratory Medicine, The Alfred Hospital and Monash University Medical School; Laboratory of Molecular Hypertension, Baker Medical Research Institute, Melbourne; and Department of Clinical Sciences, University of Tasmania Medical School, Royal Hobart Hospital, Tasmania, Australia

11beta -Hydroxysteroid dehydrogenases (11beta -HSD) are responsible for the conversion of bioactive glucocorticoids to and from inactive metabolites. 11beta -HSD2 is generally considered a high-affinity inactivator of natural glucocorticoids, although its activity with synthetic compounds in vivo is unknown. Inhaled corticosteroids (ICS) remain the primary antiinflammatory agents for treating asthma, but little is known about their metabolism in the lung. The aims of this study were to determine whether the 11beta -HSD2 enzyme can be localized to human airway tissue and whether differential expression of this enzyme relates to asthma severity and ICS needs. We studied airway biopsy specimens from 22 asthmatic subjects, in two groups: (1) a group not treated with ICS (n = 7); and (2) a group treated with ICS (range: 200 to 1,500 µg/d; n = 15). A control population consisted of nine nonasthmatic subjects. Immunostaining was done with an immunopurified antibody to human 11beta -HSD2. Immunoreactivity was generally localized to the endothelium of vessels in the lamina propria and to airway epithelium both in asthmatic patients and nonasthmatic controls. There was a statistically significant inverse relationship between the ICS dose required for effective treatment and the extent of epithelial 11beta -HSD2 staining (r = -0.44; p = 0.04). This is consistent with 11beta -HSD2 acting as an oxidoreductase that regenerates rather than inactivates ICS. This study suggests that glucocorticoid sensitivity in the lung is not determined by ICS breakdown, but may be related to 11beta -HSD2 sustaining the activation of synthetic glucocorticoids.




This article has been cited by other articles:


Home page
 Am. J. Respir. Crit. Care Med.Home page
S. E. Wenzel, H. W. Chu, P. Silkoff, S. O'Sullivan, L. Poulter, M. Akveld, and C. M. Burke
Ensuring Quality in Pharmaceutical Studies
Am. J. Respir. Crit. Care Med., October 15, 2003; 168(8): 1010 - 1012.
[Full Text]

Home page
 Am. J. Respir. Crit. Care Med.Home page
S. Suzuki, K. Koyama, A. Darnel, H. Ishibashi, S. Kobayashi, H. Kubo, T. Suzuki, H. Sasano, and Z. S. Krozowski
Dexamethasone Upregulates 11{beta}-Hydroxysteroid Dehydrogenase Type 2 in BEAS-2B Cells
Am. J. Respir. Crit. Care Med., May 1, 2003; 167(9): 1244 - 1249.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
M. J. Tobin
Asthma, Airway Biology, and Nasal Disorders in AJRCCM 2002
Am. J. Respir. Crit. Care Med., February 1, 2003; 167(3): 319 - 332.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Cell Mol. Biol.
Copyright © 2002 American Thoracic Society